Understanding the Market | HENLIUS rises over 4% as two latest research results of SLR171 in the field of gastric cancer are selected for IGCC 2025
I'm PortAI, I can summarize articles.
HENLIUS's stock price rose by more than 4%, with an increase of 4.45% as of the time of publication, priced at HKD 31.7, with a transaction volume of HKD 25.5134 million. The company's independently developed monoclonal antibody H drug's two gastric cancer research results were selected for the 2025 International Gastric Cancer Conference. The H drug has been approved in multiple countries for the treatment of various cancers
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments